Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 106 Leukemia 98 Lymphoma 79 Burkitt Lymphoma 52 Leukemia, Myeloid, Acute 51 Myelodysplastic Syndromes 41 Lymphoma, Non-Hodgkin 41 Lymphoma, Large B-Cell, Diffuse 35 Lymphoma, Mantle-Cell 33 Leukemia, Lymphocytic, Chronic, B-Cell 32 Leukemia, Myeloid, Accelerated Phase 30 Hodgkin Disease 29 Lymphoma, Follicular 28 Blast Crisis 27 Graft vs Host Disease 26 Congenital Abnormalities 26 Myeloproliferative Disorders 25 Leukemia, Myeloid, Chronic-Phase 25 Multiple Myeloma 24 Breast Neoplasms 23 Lymphoma, B-Cell, Marginal Zone 22 Leukemia, Myelomonocytic, Chronic 22 Lymphoma, Large-Cell, Immunoblastic 21 Primary Myelofibrosis 16 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 16 Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 16 Recurrence 15 Neoplasms, Plasma Cell 15 Dendritic Cell Sarcoma, Interdigitating 15 Anemia, Refractory, with Excess of Blasts 15

Interventions

Vinblastine 1 Methotrexate 1 Cyclophosphamide 1 Celecoxib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Survival Without Progression × Methotrexate × Clear all

NCT01285817 2023-03-13

SFCE METRO 01

Assistance Publique Hopitaux De Marseille

Phase 2 Completed

Survival Without Progression

Data powered by HemOnc (CC BY 4.0) Colophon ⚡